Abstract
A budget impact analysis that is validated will be more credible to healthcare budget holders. In this chapter, we present methods and examples for three types of validation: face validity, internal validity, and external validity. All three are equally important and should be included in every budget impact analysis. Validity should be assessed for all components of the analysis, including the model structure, assumptions, input parameter values, and results.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
In this chapter we make the simplifying assumption that the budget impact analysis is based on the introduction of a new drug to the current mix of drugs for treatment of a condition. Changes in our recommended approaches to estimate the budget impacts of other types of health care interventions (i.e., vaccines, diagnostics, surgery, and devices) are discussed in Chap. 13.
References
Asche CV, Clay E, Kharitonova E, Zah V, Ruby J, Aballea S. Budgetary impact of the utilization of buprenorphine/naloxone sublingual film and tablet for Medicaid in the United States. J Med Econ. 2015;18(8):600–11.
Barnett PG. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction. 2009;104(6):982–92. doi:10.1111/j.1360-0443.2009.02539.x. Cited in: Asche et al., 2015
Baser O, Chalk M, Fiellin DA, Gastfriend DR. Cost and utilization outcomes of opioid-dependence treatments. Am J Manag Care. 2011;17(Suppl 8):S235–48. Cited in: Asche et al., 2015
Bonita R, Solomon N, Broad JB. Prevalence of stroke and stroke-related disability. Estimates from the Auckland Stroke Studies. Stroke. 1997;28(10):1898–902. Cited in: Mar et al., 2010.
Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–7. Value Health. 2012;15(6):843–50.
Jensen IS, Halbert RJ, Rossi G, Naosy S, Iqbal SU, Xiao Z, et al. A hospital budget impact model to compare stem cell mobilization strategies: impact of primary research and direct stakeholder engagement. Eur J Hosp Pharm. 2015;22:142–9.
Mar J, Arrospide A, Comas M. Budget impact analysis of thrombolysis for stroke in Spain: a discrete event simulation model. Value Health. 2010;13(1):69–76. doi:10.1111/j.1524-4733.2009.00655.x.
Mar J, Sainz-Ezkerra M, Miranda-Serrano E. Calculation of prevalence through Markov models. Application to prevalence-based economic evaluation of thrombolysis for stroke. Med Decis Making. 2008;28(4):481–90. doi:10.1177/0272989X07312720. Cited in: Mar et al., 2010.
Sullivan SD, Mauskopf JA, Augustovski F, Caro JJ, Lee KM, Minchin M, et al. Budget impact analysis—principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5–14. doi:10.1016/j.jval.2013.08.2291.
Watkins JB, Danielson D. Improving the usefulness of budget impact analyses: a U.S. payer perspective. Value Health. 2014;17(1):3–4. doi:10.1016/j.jval.2013.09.007.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Mauskopf, J., Earnshaw, S. (2017). Validation. In: Budget-Impact Analysis of Health Care Interventions. Adis, Cham. https://doi.org/10.1007/978-3-319-50482-7_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-50482-7_9
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-50480-3
Online ISBN: 978-3-319-50482-7
eBook Packages: MedicineMedicine (R0)